Evaluation of bone safety and antiseizure medications: a multi-source pharmacovigilance and Mendelian randomization analysis - PubMed
6 days ago
- #Pharmacovigilance
- #Antiseizure medications
- #Bone safety
- Study evaluates bone safety concerns related to antiseizure medications (ASMs) using multi-source pharmacovigilance and Mendelian randomization.
- Analysis of FDA Adverse Event Reporting System (FAERS) data identified 7,688 reports linking ASMs to bone health-related adverse events.
- Disproportionality analysis revealed significant associations between ASMs and bone disorders like fractures, vitamin D deficiency, and increased alkaline phosphatase.
- Both traditional (carbamazepine, phenytoin, phenobarbital) and newer ASMs (perampanel, brivaracetam, lacosamide, zonisamide) showed associations with bone health issues.
- Network pharmacology suggested calcium and MAPK signaling pathways as potential mechanisms for ASM-induced bone disorders.
- Mendelian randomization identified genetic effects of CAT, TNFRSF9, USP48 on osteoporosis and MGP, MFN2, PLOD1, TNFRSF9 on ankle fracture.
- The study integrates real-world pharmacovigilance with genetic insights to highlight ASM-related bone safety risks and underlying biological pathways.